Literature DB >> 26101248

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Lowell E Schnipper1, Nancy E Davidson2, Dana S Wollins2, Courtney Tyne2, Douglas W Blayney2, Diane Blum2, Adam P Dicker2, Patricia A Ganz2, J Russell Hoverman2, Robert Langdon2, Gary H Lyman2, Neal J Meropol2, Therese Mulvey2, Lee Newcomer2, Jeffrey Peppercorn2, Blase Polite2, Derek Raghavan2, Gregory Rossi2, Leonard Saltz2, Deborah Schrag2, Thomas J Smith2, Peter P Yu2, Clifford A Hudis2, Richard L Schilsky2.   

Abstract

Mesh:

Year:  2015        PMID: 26101248      PMCID: PMC5015427          DOI: 10.1200/JCO.2015.61.6706

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  41 in total

1.  A method for defining value in healthcare using cancer care as a model.

Authors:  Thomas W Feeley; Helen Shafer Fly; Heidi Albright; Ronald Walters; Thomas W Burke
Journal:  J Healthc Manag       Date:  2010 Nov-Dec

2.  Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.

Authors:  Steven G Morgan; Meghan McMahon; Craig Mitton; Elizabeth Roughead; Ray Kirk; Panos Kanavos; Devidas Menon
Journal:  Health Aff (Millwood)       Date:  2006 Mar-Apr       Impact factor: 6.301

3.  American Society of Clinical Oncology 2013 top five list in oncology.

Authors:  Lowell E Schnipper; Gary H Lyman; Douglas W Blayney; J Russell Hoverman; Derek Raghavan; Dana S Wollins; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2013-10-29       Impact factor: 44.544

4.  Access, affordability, and insurance complexity are often worse in the United States compared to ten other countries.

Authors:  Cathy Schoen; Robin Osborn; David Squires; Michelle M Doty
Journal:  Health Aff (Millwood)       Date:  2013-11-13       Impact factor: 6.301

5.  Should physicians be gatekeepers of medical resources?

Authors:  M C Weinstein
Journal:  J Med Ethics       Date:  2001-08       Impact factor: 2.903

6.  Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.

Authors:  V Georgoulias; E Papadakis; A Alexopoulos; X Tsiafaki; A Rapti; M Veslemes; P Palamidas; I Vlachonikolis
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

7.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

8.  Patients' expectations about effects of chemotherapy for advanced cancer.

Authors:  Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

9.  The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.

Authors:  S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy
Journal:  Oncologist       Date:  2013-02-26

10.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

View more
  219 in total

1.  Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits.

Authors:  Peter B Bach
Journal:  Oncologist       Date:  2015-08-11

2.  Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Authors:  Boris Freidlin; Richard F Little; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

3.  Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.

Authors:  Stacie B Dusetzina; Nancy L Keating
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

4.  Communication with Physicians about Health Care Costs: Survey of an Insured Population.

Authors:  Nora B Henrikson; Eva Chang; Kevin Ulrich; Deborah King; Melissa L Anderson
Journal:  Perm J       Date:  2017

5.  Financial Hardship and Quality of Life among African American and White Cancer Survivors: The Role of Limiting Care Due to Cost.

Authors:  Theresa A Hastert; Jaclyn M Kyko; Amanda R Reed; Felicity W K Harper; Jennifer L Beebe-Dimmer; Tara E Baird; Ann G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-05-06       Impact factor: 4.254

Review 6.  Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.

Authors:  Meng Qiao; Tao Jiang; Caicun Zhou
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

7.  Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care.

Authors:  Ya-Chen Tina Shih; Shelley Fuld Nasso; S Yousuf Zafar
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

8.  Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer.

Authors:  Massimo Di Maio; Paolo Bironzo; Giorgio Vittorio Scagliotti
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 9.  Bending the Cost Curve in Childhood Cancer.

Authors:  Heidi Russell; M Brooke Bernhardt
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

10.  Oncologist Support for Consolidated Payments for Cancer Care Management in the United States.

Authors:  Siva Narayanan; Emily Hautamaki
Journal:  Am Health Drug Benefits       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.